Does Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide Interact with P Gp Or Bcrp Substrates?
CDI records a moderate classification for Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and P Gp Or Bcrp Substrates. The stored summary is: Co-administration may result in increased plasma concentrations of P-gp substrates due to transporter inhibition. The mechanism involves cobicistat inhibits p-glycoprotein transporter. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide Class
- Cytochrome P450 3A Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Cobicistat inhibits P-glycoprotein transporter
What To Tell Your Doctor or Pharmacist
If you are taking Darunavir Cobicistat Emtricitabine And Tenofovir Alafenamide and your doctor is considering prescribing P Gp Or Bcrp Substrates (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider